In a move aimed at making healthcare more affordable, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 30 drug formulations used to treat a range of health conditions, including vitamin deficiencies, diabetes, cardiovascular diseases, allergies, infections, and other chronic illnesses.
The decision covers several commonly prescribed medicines, including Vitamin D3 oral solutions, calcium and vitamin supplements, anti-diabetic drugs, heart medications, and immunosuppressant therapies.
By regulating the prices of these formulations, the government hopes to reduce treatment costs for patients who rely on long-term medication.
According to the notification issued under the Drugs (Prices Control) Order (DPCO), 2013, the newly fixed prices will apply to specific formulations categorized as “new drugs.” Manufacturers and marketing companies listed in the order will be required to sell these medicines at or below the prescribed retail prices.
Among the notable formulations included in the price control order are Vitamin D3 supplements, calcium-based nutritional tablets, medicines used to manage cholesterol levels, blood pressure medications, anti-allergy treatments, and combination drugs for diabetes management. The notification also covers certain medicines used by organ transplant patients and individuals requiring specialized therapies.
The NPPA stated that the notified prices are exclusive of GST, which may be charged separately if applicable. Manufacturers must update their price lists and ensure compliance with the revised rates.
The move is expected to benefit millions of patients across the country, particularly those suffering from chronic conditions that require continuous treatment. Rising healthcare expenses have been a concern for many households, and price regulation of essential medicines is seen as a step toward improving affordability and access.
The authority has also warned that companies charging prices higher than the approved rates could face action under the provisions of the DPCO, 2013, and the Essential Commodities Act.
Healthcare experts believe the decision will provide financial relief to patients while helping ensure wider access to important medicines. The latest notification is part of the government’s ongoing efforts to keep essential and life-saving treatments within reach of the general public.
